NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer

被引：0
|
作者：
Meng Ren
Hongyu Zhao
Yan Gao
Qi Chen
Xiaoting Zhao
Wentao Yue
机构：
[1] Capital Medical University,Central Laboratory, Beijing Obstetrics and Gynecology Hospital
[2] Beijing Maternal and Child Health Care Hospital,undefined
[3] Center for Discovery and Innovation,undefined
[4] Hackensack Meridian Health,undefined
来源：
Journal of Ovarian Research | / 16卷
关键词：
NUF2; Ovarian cancer; HNRNPA2B1; PI3K/AKT/mTOR signaling pathway;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Clarifying intratumoral heterogeneity in ovarian cancer via transcriptomic analysis of the PI3K/AKT/mTOR pathway
    Shen, Yang
    Yin, Han
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S167 - S168
  • [22] IMMT promotes hepatocellular carcinoma formation via PI3K/AKT/mTOR pathway
    Wang, Jiabei
    Zhang, Yunguang
    Sun, Linmao
    Liu, Yao
    ONCOLOGIE, 2023, 25 (06) : 691 - 703
  • [23] NUCKS1 promotes the progression of colorectal cancer via activating PI3K/AKT/mTOR signaling pathway
    Zhu, Liao-Liao
    Shi, Jing-Jie
    Guo, Yong-Dong
    Yang, Cheng
    Wang, Rong-Lin
    Li, Shan-Shan
    Gan, Dong-Xue
    Ma, Pei-Xiang
    Li, Jun-Qiang
    Su, Hai-Chuan
    NEOPLASMA, 2023, 70 (02) : 272 - 286
  • [24] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
    Chen, Jiezhong
    Zhao, Kong-Nan
    Li, Rui
    Shao, Renfu
    Chen, Chen
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
  • [25] GLUD1 suppresses renal tumorigenesis and development via inhibiting PI3K/Akt/mTOR pathway
    Wang, Lei
    Fang, Zhiyu
    Gao, Peixiang
    Zheng, Junfang
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [26] NUF2 overexpression contributes to epithelial ovarian cancer progression via ERBB3-mediated PI3K-AKT and MAPK signaling axes
    Leng, Ruobing
    Meng, Yunfang
    Sun, Xiaomei
    Zhao, Yingzi
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [27] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [28] PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?
    Gasparri, Maria Luisa
    Bardhi, Erlisa
    Ruscito, Ilary
    Papadia, Andrea
    Farooqi, Ammad Ahmad
    Marchetti, Claudia
    Bogani, Giorgio
    Ceccacci, Irene
    Mueller, Michael D.
    Panici, Pierluigi Benedetti
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2017, 77 (10) : 1095 - 1103
  • [29] PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer
    Aziz, Aziz Ur Rehman
    Farid, Sumbal
    Qin, Kairong
    Wang, Hanqin
    Liu, Bo
    BIOMOLECULES, 2018, 8 (01)
  • [30] EMP-1 Promotes Tumorigenesis of NSCLC through PI3K/AKT Pathway
    来森艳
    王桂华
    曹小年
    李兆明
    胡俊波
    王晶
    Current Medical Science, 2012, (06) : 834 - 838
12345